Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~Exclusion Criteria:~* Receipt of Seasonal Influenza Vaccine for season 2007/2008~* Receipt of another vaccine within 3 weeks before and after each vaccination~* Previous vaccination with a pandemic candidate vaccine and/or vaccine containing the adjuvant MF59 or a similar adjuvant~* Children who are in the local recommendation for influenza vaccination due to underlying diseases

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): 0.5mL of H5N1 vaccine 7.5ug
- Arm 2 (Type: ACTIVE_COMPARATOR): 0.25 or 0.5mL of H5N1 vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).